Healthcare - Biotechnology - NASDAQ - US
$ 1.59
-1.85 %
$ 43.6 M
Market Cap
-1.92
P/E
CASH FLOW STATEMENT
-11.4 M
OPERATING CASH FLOW
-52.1 K
INVESTING CASH FLOW
15.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immix Biopharma, Inc.
| Net Income | -15.6 M |
| Depreciation & Amortization | 5.47 K |
| Capital Expenditures | -52.1 K |
| Stock-Based Compensation | 2.57 M |
| Change in Working Capital | 1.65 M |
| Others | -782 K |
| Free Cash Flow | -11.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (15.6) | (8.2) | (24.4) | (1.1) | (1.0) |
| Depreciation & Amortization | 5.47 K | 2.14 K | 2.47 K | 2.32 K | 1.08 K |
| Deferred Income Tax | 0 | 0 | 22.8 | 0 | 0 |
| Stock Based Compensation | 2.6 | 0.6 | 0.2 | 0 | 0 |
| Other Operating Activities | 0 | 100 K | 0.1 | 0.6 | 84.5 K |
| Change in Working Capital | 1.7 | 0.2 | (0.4) | 0.2 | 0.2 |
| Cash From Operations | (11.4) | (7.4) | (1.6) | (0.4) | (0.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 52.1 K | 0 | 802 | 0 | 7.31 K |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 52.1 K | 0 | 802 | 0 | 7.31 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 100 K | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0.2 | 0 | 1.1 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.2) | 56.7 K | 0 | 0 | 0 |
| Cash From Financing Activities | 15.5 | 3.2 | 18.8 | 0 | 1.1 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 4.1 | (4.2) | 17.3 | (0.3) | 0.3 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (11.4) | (7.4) | (1.6) | (0.4) | (0.8) |